A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) (NCT07227402)
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib. The goal of this study is to learn if: People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.
Who can join: Review the eligibility criteria below.
Location: Alaska Oncology and Hematology ( Site 0133) — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (127 Sites)
Showing the first 25 of 127 sites.
- Alaska Oncology and Hematology ( Site 0133) — Anchorage, Alaska
- Providence Medical Foundation ( Site 0141) — Fullerton, California
- USC Norris Comprehensive Cancer Center ( Site 0126) — Los Angeles, California
- Cedars-Sinai Medical Center ( Site 0112) — Los Angeles, California
- New England Cancer Specialists ( Site 0132) — Westbrook, Maine
- Greater Baltimore Medical Center ( Site 0145) — Baltimore, Maryland
- Metro-Minnesota Community Clinical Oncology ( Site 0144) — Saint Louis Park, Minnesota
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0131) — Omaha, Nebraska
- Carolina Oncology Specialists, PA ( Site 9002) — Charlotte, North Carolina
- Thompson Cancer Survival Center ( Site 0125) — Knoxville, Tennessee
- Hospital Aleman ( Site 0204) — CABA, Buenos Aires
- Hospital Italiano de Buenos Aires. ( Site 0203) — Caba, Buenos Aires
- Asociación de Beneficencia Hospital Sirio Libanés ( Site 0205) — Caba, Buenos Aires
- Instituto Alexander Fleming ( Site 0202) — CABA, Buenos Aires
- Hospital Universitario Austral ( Site 0212) — Pilar, Buenos Aires
- Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0208) — Caba., Buenos Aires F.D.
- Sanatorio Parque ( Site 0201) — Rosario, Santa Fe Province
- Instituto de Oncología de Rosario ( Site 0209) — Rosario, Santa Fe Province
- Hospital Privado Universitario de Córdoba ( Site 0207) — Córdoba,
- Macquarie University-MQ Health Clinical Trials Unit ( Site 2100) — Sydney, New South Wales
- Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 0600) — Linz, Upper Austria
- Medizinische Universitat Wien ( Site 0601) — Vienna,
- Cliniques Universitaires Saint-Luc ( Site 0703) — Brussels, Bruxelles-Capitale, Region de
- Ziekenhuis Oost-Limburg, Campus St.-Jan ( Site 0701) — Genk, Limburg
- UZ Gent ( Site 0702) — Ghent, Oost-Vlaanderen
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Renal Cell Carcinoma
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma — Birmingham, Alabama
- 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma — Dallas, Texas
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma — Stanford, California
- Follow-up After Metastasectomy in Patients With Kidney Cancer — Houston, Texas
- Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma — La Jolla, California
- A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors — Los Angeles, California
Explore by condition: All Renal Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.